T0901317

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H12F9NO3S
Molecular Weight	481.333
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(C1=CC=C(C=C1)N(CC(F)(F)F)S(=O)(=O)C2=CC=CC=C2)(C(F)(F)F)C(F)(F)F

InChI

InChIKey=SGIWFELWJPNFDH-UHFFFAOYSA-N

InChI=1S/C17H12F9NO3S/c18-14(19,20)10-27(31(29,30)13-4-2-1-3-5-13)12-8-6-11(7-9-12)15(28,16(21,22)23)17(24,25)26/h1-9,28H,10H2

HIDE SMILES / InChI

Molecular Formula	C17H12F9NO3S
Molecular Weight	481.333
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10968783
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23665929 | https://www.ncbi.nlm.nih.gov/pubmed/15464433

T0901317 is a potent, high affinity liver X receptors (LXRs) agonist. It upregulates expression of the ABCA1 gene associated with cholesterol efflux regulation and high-density lipoproteins metabolism. It also exhibits inverse agonist activity at constitutive androstane receptors (CARs). T0901317 activates bile acid farnesoid X receptors (FXRs), and it is 10-fold more potent than natural FXR ligand chenodeoxycholic acid.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Bile acid receptor FXR 31 Target ID: CHEMBL2047 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15464433	Agonist 2678	5.0 µM [EC50]
LXR-alpha 10 Target ID: CHEMBL2808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11090131	Agonist 2678	20.0 nM [IC50]
LXR-beta 6 Target ID: CHEMBL4093 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10968783	Agonist 2678	50.0 nM [Kd]
Nuclear receptor subfamily 1 group I member 3 4 Target ID: CHEMBL5503 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23665929	Inverse Agonist 80	2.2 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Unknown 2578

PubMed

Title	Date	PubMed
Role of LXRs in control of lipogenesis.	2000 Nov 15	11090131
Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers.	2000 Sep 1	10968783
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease.	2005 Feb 11	15557325
T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR.	2007 May 1	17418145
TO901317, a potent LXR agonist, is an inverse agonist of CAR.	2013	23665929
Liver X receptor agonist T0901317 enhanced peroxisome proliferator-activated receptor-delta expression and fatty acid oxidation in rat skeletal muscle.	2013 Jun	23959725

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

HEK293 cells transfected with human LXRalpha and LXR response elements were treated with increasing concentrations of T0901317 or endogenous LXR ligand, 24(S),25-epoxycholesterol (24,25-EC). Synthetic ligand induced transcriptional activity of LXRalpha nearly eightfold with EC50 value of 20 nM. T0901317 appeared significantly more active than 24,25-EC, which displayed an EC50 value of 3 uM.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:55:19 GMT 2023` Edited by `admin` on `Sat Dec 16 08:55:19 GMT 2023`
Record UNII	A07663A39I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

T0901317

Common Name

English

T-1317

Code

English

N-(2,2,2-TRIFLUOROETHYL)-N-(4-(2,2,2-TRIFLUORO-1-HYDROXY-1-(TRIFLUOROMETHYL)ETHYL)PHENYL)BENZENESULFONAMIDE

Systematic Name

English

BENZENESULFONAMIDE, N-(2,2,2-TRIFLUOROETHYL)-N-(4-(2,2,2-TRIFLUORO-1-HYDROXY-1-(TRIFLUOROMETHYL)ETHYL)PHENYL)-

Systematic Name

English

T-0901317

Code

English

J1.503.100J

Code

English

TO-901317

Code

English

Code System Code Type Description

FDA UNII

A07663A39I